{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-26-000027","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-08-12T20:13:33+00:00","discovered_at":"2026-08-12T20:14:00.259916+00:00","generated_at":"2026-08-12T20:14:05.655281+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Connect Biopharma Q2 net loss $17.3M; enrollment done in both Seabreeze STAT trials","bullets":["Q2 2026 net loss $17.3M ($0.27/share) vs $12.9M ($0.23) in Q2 2025; H1 loss $36.7M ($0.61).","Cash, equivalents, short-term investments $31.5M at June 30, 2026; runway at least one year.","Enrollment completed in Phase 2 Seabreeze STAT asthma (160 pts) and COPD (159 pts) studies; topline results expected September 2026.","Initiated open-label Phase 2 Seabreeze STAT IV trial (40 participants) evaluating IV rademikibart for acute exacerbations.","Simcere license revenue $2.8M in Q2 (vs $48K prior year); eligible for up to ~$99M in remaining milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-26-000027","json":"https://secwatch.observer/filing/0001835268-26-000027.json","markdown":"https://secwatch.observer/filing/0001835268-26-000027.md","text":"https://secwatch.observer/filing/0001835268-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/0001835268-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/cntb-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:14:05.655281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}